Zobrazeno 1 - 10
of 121
pro vyhledávání: '"A. Sánchez-Gastaldo"'
Autor:
Candal-Pedreira, Cristina, Ruano-Ravina, Alberto, Calvo de Juan, Virginia, Cobo, Manuel, Trigo, José Manuel, Rodríguez-Abreu, Delvys, Estival, Anna, Carcereny, Enric, Cucurull, Marc, López Castro, Rafael, Medina, Andrea, García Campelo, Rosario, Cordeiro González, Patricia, Sánchez-Gastaldo, Amparo, Bosch-Barrera, Joaquim, Massutí, Bartomeu, Dómine, Manuel, Camps, Carlos, Ortega, Ana Laura, Sánchez-Hernández, Alfredo, Guirado Risueño, María, del Barco Morillo, Edel, Garrido Fernández, Alberto, Provencio, Mariano
Publikováno v:
In Archivos de Bronconeumología February 2024 60(2):88-94
Autor:
Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern
Externí odkaz:
https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to descri
Externí odkaz:
https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d
Autor:
Edurne Arriola, MD, PhD, José Manuel Trigo, MD, Amparo Sánchez-Gastaldo, MD, Alejandro Navarro, MD, Coral Perez, MD, Leonardo Crama, MD, Santiago Ponce-Aix, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100266- (2022)
Introduction: SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive stage. This study aimed to evaluate the prognostic value of TNM staging in a real
Externí odkaz:
https://doaj.org/article/ee4d170a7bb04b6b9b63698467121349
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. Falcón González, P. Estévez Garcia, A. Sánchez Gastaldo, I. Sánchez Simón, J. Salvador Boffil, M. Ruiz Borrego
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100314- (2021)
HER2-positive metastatic breast cancer is an aggressive disease with a limited number of treatment options. In the last 15 years, new drugs such as trastuzumab, pertuzumab, lapatinib or trastuzumab emtansine (TDM-1) have sprouted for these patients.
Externí odkaz:
https://doaj.org/article/0a002d5e6ca847738a8a7f4a2d50de59
Autor:
Miriam Alonso-García, Amparo Sánchez-Gastaldo, Miguel A. Muñoz-Fuentes, Sonia Molina-Pinelo, Laura Boyero, Johana Cristina Benedetti, Reyes Bernabé-Caro
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 533 (2022)
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy
Externí odkaz:
https://doaj.org/article/6c4ab7e0320e4541932945c15fccdbcf
Autor:
Alonso-García, Miriam1 (AUTHOR) miriamag3@hotmail.com, Sánchez-Gastaldo, Amparo1,2 (AUTHOR) asanchezgastaldo@gmail.com, Muñoz-Fuentes, Miguel A.2 (AUTHOR) pinelo_sonia@hotmail.com, Molina-Pinelo, Sonia2,3 (AUTHOR) lboyero@hotmail.com, Boyero, Laura2 (AUTHOR), Benedetti, Johana Cristina1,2 (AUTHOR) benedettipedroza@gmail.com, Bernabé-Caro, Reyes1,2 (AUTHOR) reyesbernab@yahoo.es
Publikováno v:
Pharmaceuticals (14248247). May2022, Vol. 15 Issue 5, p533-533. 14p.
Publikováno v:
Oncology and Therapy; March 2024, Vol. 12 Issue: 1 p175-182, 8p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.